Company Encyclopedia
View More
name
Zivo Bioscience
ZIVO.US
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc.
506.31 B
ZIVO.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
Personal Care ProductsIndustry
Industry Ranking30/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE316.07%A
    • Profit Margin-4059.73%E
    • Gross Margin32.44%C
  • Growth ScoreA
    • Revenue YoY164.52%A
    • Net Profit YoY38.02%B
    • Total Assets YoY12.89%B
    • Net Assets YoY-57.78%E
  • Cash ScoreB
    • Cash Flow Margin-2.46%D
    • OCF YoY164.52%A
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreE
    • Gearing Ratio687.47%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zivo Bioscience | 10-Q: FY2025 Q3 Revenue: USD 65.63 K

    LB filings·
    US
    ZIVO
    -11.21%
    LB filings·
    US
    ZIVO
    -11.21%

    Major Investment Alert: Zivo Bioscience Sees Significant Shareholder Action

    Mark E. Strome has invested $249,996 in Zivo Bioscience by acquiring 20,259 shares. However, Spark's AI Analyst rates ZIVO as an Underperform due to significant financial challenges, including negative equity and cash flow issues. The company requires urgent financial restructuring for sustainability, with a year-to-date price performance of -41.73% and a current market cap of $47.75M.

    Tip Ranks·
    US
    ZIVO
    -11.21%
    Tip Ranks·
    US
    ZIVO
    -11.21%

    10% Owner Mark E. Strome Acquires Common Shares of Zivo Bioscience Inc

    Mark E. Strome, a 10% owner of Zivo Bioscience Inc., has reported the acquisition of common shares along with other beneficial owners. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

    Reuters·
    US
    ZIVO
    -11.21%
    Reuters·
    US
    ZIVO
    -11.21%

    Director Makes Bold Move with Major Stock Purchase in Zivo Bioscience!

    Director Laith L. Yaldoo has purchased 1,659 shares of Zivo Bioscience, valued at $19,990, signaling confidence in the company. However, Spark's AI Analyst rates ZIVO as Underperform due to financial challenges, including negative equity and cash flow issues. The company has a year-to-date price performance of -36.52% and a market cap of $50.38M, indicating urgent need for financial restructuring.

    Tip Ranks·
    US
    ZIVO
    -11.21%
    Tip Ranks·
    US
    ZIVO
    -11.21%

    Zivo Bioscience Inc. Director and 10% Owner Laith L. Yaldoo Reports Acquisition of Common Shares

    Laith L. Yaldoo, Director and 10% Owner of Zivo Bioscience Inc., has reported the acquisition of common shares in the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

    Reuters·
    US
    ZIVO
    -11.21%
    Reuters·
    US
    ZIVO
    -11.21%